Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolin, Edward M, Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A, Tomassetti, Paola, Weber, Matthias M, Fogelman, David R, Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L, Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562767/
https://www.ncbi.nlm.nih.gov/pubmed/26366058
http://dx.doi.org/10.2147/DDDT.S84177

Ejemplares similares

Ejemplares similares